United States Health

Telix (NASDAQ:TLX) received U.S. Food and Drug Administration approval for Pixclara, or floretyrosine F 18, as a PET imaging drug for evaluating glioma.

Radiopharm Theranostics (NASDAQ:RADX) reported that RAD101 PET achieved 93% concordance with MRI across all evaluable lesions in an interim Phase 2b analysis, meeting the imaging trial’s primary endpoint.

Perspective Therapeutics entered a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate targeted alpha therapy PSV359 in combination with Keytruda in FAP-α-positive solid tumors.

Digital Realty (NYSE:DLR) formed a strategic joint venture with Rönesans Infrastructure to develop and operate next-generation, carrier-neutral data centers across Türkiye.

BioNTech (NASDAQ:BNTX) and OncoC4 reported updated Phase 3 PRESERVE-003 data showing median overall survival of 18.5 months with gotistobart versus 10.0 months with docetaxel in previously treated squamous NSCLC.

Cullinan Therapeutics (NASDAQ:CGEM), Taiho Oncology, and Taiho Pharmaceutical reported that zipalertinib plus chemotherapy improved median progression-free survival by six months versus chemotherapy alone in the Phase 3 REZILIENT3 trial.

Whitehawk Therapeutics (NASDAQ:WHWK) reported WCLC 2026 real-world analyses supporting protein tyrosine kinase 7, or PTK7, as a potential antibody-drug conjugate target in pretreated EGFR wild-type non-small cell lung cancer.

Johnson & Johnson (NYSE:JNJ) reported final Phase 3 PAPILLON results showing median overall survival of 34.3 months with first-line IV RYBREVANT plus carboplatin-pemetrexed versus 27.9 months with chemotherapy alone.

AstraZeneca (NASDAQ:AZN) reported updated Phase III ADAURA results showing TAGRISSO reduced the risk of death by 48% versus placebo after eight years in the overall Stage IB-IIIA EGFR-mutated NSCLC population.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo reported that ENHERTU achieved median progression-free survival of 14.3 months in the Phase III DESTINY-Lung04 lung cancer trial.

Nanobiotix (NASDAQ:NBTX) reported complete Phase 1 full-cohort results for radiotherapy-activated JNJ-1900, formerly NBTXR3, in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation.

Takeda (NYSE:TAK) said the U.S. FDA accepted its New Drug Application for zasocitinib under Priority Review for adults with moderate-to-severe plaque psoriasis.